Niagen Bioscience, Inc. will announce its financial results for the second quarter ended June 30, 2026, on Tuesday, August 4, 2026. The company will release the results after the close of regular stock market trading hours. A conference call is scheduled for 4:30 p.m. ET to discuss the performance and provide a general business update.

Conference Call Details

Investors can access the live webcast or dial-in to listen to the discussion. The call will cover Niagen Bioscience’s second quarter financial results and business outlook.

The earnings press release and financial exhibits will be available in the Investor Relations section of Niagen Bioscience’s website at www.niagenbioscience.com .

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) focuses on the science of healthy aging and NAD+ (nicotinamide adenine dinucleotide). The company’s product portfolio includes Niagen®, a patented nicotinamide riboside, and Tru Niagen®, an oral supplement. Its subsidiary, NAD Pharmaceuticals Corp., is researching therapies for accelerated aging and rare genetic diseases.

Niagen Bioscience, Inc. (NASDAQ: NAGE) has appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will lead the company's Global Niagen Research Program, overseeing its worldwide network of academic and clinical research collaborations and shaping its scientific research strategy. This appointment aims to deepen the company's engagement with leading investigators to advance discoveries in NAD+ biology and age-related health.

Leadership and Strategy

"Science informs our strategy and our messaging, not the other way around," said Rob Fried, CEO of Niagen Bioscience. The company emphasized that Dr. Kale's role will involve working closely with investigators to strengthen Niagen Bioscience's position as a scientific authority in NAD+ research. Dr. Kale brings over a decade of experience in aging biology, translational science, and external scientific partnerships.

Professional Background

Dr. Kale most recently served as a Scientific Review Officer at Hevolution Foundation, where he evaluated more than 600 research proposals and contributed to funding recommendations across a $1 billion global longevity research portfolio. His previous roles include scientific leadership positions at the Buck Institute for Research on Aging, Deciduous Therapeutics, and LevitasBio. He earned his Ph.D. in Molecular Genetics from Albert Einstein College of Medicine and has authored 16 publications, including foundational research on NAD+ biology and aging.

Niagen Research Program

The Global Niagen Research Program is a scientific collaboration initiative in the healthspan field. Independent investigators from institutions such as Mayo Clinic, National Institutes of Health (NIH), Harvard University, MIT, and Cambridge University participate in the program. It provides oral food-grade and pharmaceutical-grade Niagen material, scientific collaboration, and technical support.

Research Focus and Expansion

Research under the program spans healthy aging, metabolism, mitochondrial function, cognitive and cardiovascular health, inflammation, and rare diseases. The program has also expanded into indications such as Peripheral Artery Disease and Ataxia Telangiectasia. Under Dr. Kale's leadership, Niagen Bioscience plans to expand the program to support emerging areas of NAD+ science, including pharmaceutical-grade Niagen injections and infusions, topical applications, and research on other NAD+ precursors.